Market Overview

UPDATE: Benchmark Company Reiterates Speculative Buy Rating, Lowers PT on Chembio Diagnostics


In a report published Wednesday, Benchmark Company reiterated its Speculative Buy rating on Chembio Diagnostics (NASDAQ: CEMI), but lowered its price target from $14.00 to $10.00.

Benchmark noted, “Order volumes have been lumpy with Q4 reportedly benefiting from a record backlog at the expense of Q3 results. Most important, Management disclosed it believes its DPP HIV test successfully concluded its FDA pre-approval inspection during October. We anticipate this is the last significant hurdle prior to FDA marketing clearance likely in December of January. This DPP-HIV test is the first of at least three significant new rapid diagnostics that Chembio is developing to target syphilis, HIV and hepatitis-C (HCV) over the 2013-2015 timeframe. We are increasingly optimistic in this pipeline but based on diminished recent results we trimmed our out-year EPS forecast and cut our price target to $10, from $14.”

Chembio Diagnostics closed on Tuesday at $4.12.

Latest Ratings for CEMI

Apr 2020BenchmarkMaintainsSpeculative Buy
Mar 2020BenchmarkMaintainsSpeculative Buy
Jan 2019Canaccord GenuityInitiates Coverage OnBuy

View More Analyst Ratings for CEMI
View the Latest Analyst Ratings


Related Articles (CEMI)

View Comments and Join the Discussion!

Posted-In: Benchmark CompanyAnalyst Color Price Target Analyst Ratings

Latest Ratings

TFCWells FargoMaintains35.0
GSWells FargoMaintains198.0
AMTDWells FargoMaintains36.0
SFWells FargoMaintains38.0
REGNWells FargoMaintains435.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at